NRX Pharmaceuticals (NRXP) Preferred Stock Liabilities (2017 - 2019)
NRX Pharmaceuticals (NRXP) posted quarterly Preferred Stock Liabilities of $24.5 million for Q4 2019, down 62.04% year-over-year from $64.5 million in Q4 2018, and down 28.47% quarter-over-quarter from $34.3 million in Q3 2019.
NRX Pharmaceuticals (NRXP) Preferred Stock Liabilities (2017 - 2019) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Preferred Stock Liabilities for 3 consecutive years, with $24.5 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Preferred Stock Liabilities fell 62.04% year-over-year to $24.5 million; the TTM figure through Dec 2019 stood at $24.5 million (down 62.04% YoY), while the FY2019 annual figure was $24.5 million, down 62.04% from the prior year.
- Preferred Stock Liabilities eased to $24.5 million in Q4 2019 per NRXP's latest filing, from $34.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $64.7 million in Q1 2019 and bottomed at $24.5 million in Q4 2019.
- Historically, Preferred Stock Liabilities has averaged $54.3 million across 3 years, with a median of $64.5 million in 2018.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 0.37% in 2019 and fell as far as 62.04% in 2019.
- NRX Pharmaceuticals' Preferred Stock Liabilities stood at $64.5 million in 2017, then increased by 0.1% to $64.5 million in 2018, then plunged by 62.04% to $24.5 million in 2019.
- Business Quant data shows NRXP's Preferred Stock Liabilities at $24.5 million in Q4 2019, $34.3 million in Q3 2019, and $43.0 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 24.50 Mn |
| Sep 30, 2019 | 34.25 Mn |
| Jun 30, 2019 | 42.99 Mn |
| Mar 31, 2019 | 64.73 Mn |
| Dec 31, 2018 | 64.54 Mn |
| Sep 30, 2018 | 64.51 Mn |
| Jun 30, 2018 | 64.48 Mn |
| Mar 31, 2018 | 64.49 Mn |
| Dec 31, 2017 | 64.47 Mn |